Scientists develop novel drug that could potentially treat liver cancer more effectively

August 3, 2018, National University of Singapore
Professor Daniel Tenen (right) and Dr Liu Bee Hui (left), who are researchers from the Cancer Science Institute of Singapore at the National University of Singapore, are members of the research team that had developed a novel peptide drug that could potentially treat liver cancer more effectively. Credit: National University of Singapore

A research team led by scientists from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC), or primary liver cancer. This landmark discovery opens the door for more effective treatment of liver cancer with less side effects.

The international team comprises researchers from Brigham and Women's Hospital at Harvard Medical School, the Department of Biological Sciences under the NUS Faculty of Science, as well as the Agency for Science, Technology and Research.

HCC is a fast-growing of the liver, and patients typically survive 11 months after diagnosis. HCC accounts for over 90 percent of all liver cancers and poses a major public health problem in the Asia Pacific region. The main first-line treatment for HCC is the drug Sorafenib, which has adverse side effects and prolongs survival for only three months. The lack of alternatives, coupled with late discovery, has led to HCC becoming the second leading cause of cancer deaths worldwide.

SALL4—a protein related to tumour growth—has been widely studied as a prognosis marker and drug target for HCC and other cancers such as lung cancer and leukaemia. It is usually present in the growing foetus, but is inactive in adult tissue. In some types of cancer, such as HCC, SALL4 is reactivated, leading to the growth of tumours. However, SALL4 has previously been classified as an undruggable target.

Novel peptide with robust anti-tumour properties

Drug molecules that act on protein interactions like SALL4-NuRD often require the target proteins to have a small 'pocket' in their 3-D structure where the drug molecule can reside and take effect. "In our earlier research, we found out that the SALL4 protein works with another protein, NuRD, to form a partnership that is crucial for the development of cancers such as HCC. Instead of looking for 'pockets' on SALL4, our research team designed a bio-molecule to block the interaction between SALL4 and NuRD. In our lab experiments, blocking this interaction has led to tumour cell death and reduced movement of tumour cells," explained Professor Daniel Tenen, Director of CSI Singapore.

He added, "This exciting discovery has important implications for treatment of HCC. Our work could also be beneficial to a broad range of solid cancers and leukaemic malignancies with elevated SALL4."

The research team also discovered that FFW, when used in combination with Sorafenib, could reduce the growth of Sorafenib-resistant HCC.

While most targeted therapies are small-molecule drugs, a well-designed peptide drug—such as FFW—tends to possess higher selectivity over large binding surfaces with a safer toxicity profile compared with small molecules.

Dr. Liu Bee Hui, Research Fellow at CSI Singapore, said, "Based on the information we gained from structural and global gene expression, we are continuing our work on this peptide and other peptides with similar structures, with the aim of eventually being able to make them into clinical grade drugs for the benefit of patients."

New approach in cancer therapeutics

The targeting of the SALL4-NuRD interaction as a cancer-cell-specific target represents an exciting avenue for development of therapeutic options.

"An ideal cancer target should be cancer-specific and non-toxic to normal tissues. To this end, we are collaborating to find a missing link that can cure cancer and restore normal cell function," explained Associate Professor Li Chai from Brigham and Women's Hospital at Harvard Medical School.

The research team utilised a creative and innovative integrated approach, combined with structural analysis techniques, to act on protein interactions like SALL4-NuRD. The collaborative effort led to the design of the peptide FFW, which is a small chain of amino acids that can interfere with SALL4-NuRD interactions. FFW could effectively block the huge protein-protein interaction surface and does not require a 'pocket' to take effect.

"In our latest work, the research team has also demonstrated an effective strategy to accurately target oncogenes previously considered undruggable. Moving forward, we hope to investigate how the targeting of these protein interactions might pan out in other cancer types," Prof Tenen said.

Explore further: New discoveries pave the way for early screening of liver cancer patients for targeted therapy

More information: Bee Hui Liu et al, Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1801253115

Related Stories

New discoveries pave the way for early screening of liver cancer patients for targeted therapy

June 13, 2013
Latest research findings by scientists at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) could enable early screening of patients with hepatocellular carcinoma (HCC), ...

'Undruggable' may be druggable: A new target for cancer drug development

June 17, 2013
Harvard Stem Cell Institute (HSCI) researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

After 60 years, scientists uncover how thalidomide produced birth defects

August 1, 2018
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Researchers find protein that marks difference between cancer and non-cancer cells

March 8, 2018
A discovery sheds light on how cancerous cells differ from healthy ones, and could lead to the development of new strategies for therapeutic intervention for difficult-to-treat cancers in the future.

Recommended for you

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

New clues into how 'trash bag of the cell' traps and seals off waste

August 15, 2018
The mechanics behind how an important process within the cell traps material before recycling it has puzzled scientists for years. But Penn State researchers have gained new insight into how this process seals off waste, ...

RUNX proteins act as regulators in DNA repair, study finds

August 15, 2018
A study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia (FA) ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.